Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Discovery Fund

Lilly drops touted Zyprexa successor for use in schizophrenia

Pomaglumetad methionil disappoints in phase III

- PMLiVE

Lilly’s Alzheimer’s drug solanezumab stumbles, but doesn’t fall in phase III

Fails to show significant benefit, but data holds some consolation

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

- PMLiVE

Interview: Jan Lundberg, Eli Lilly

We talk to Jan Lundberg, executive VP, science and technology, and president, Lilly Research Laboratories

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links